

Siddhartha Jaiswal

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6987490/publications.pdf>

Version: 2024-02-01

51
papers

14,827
citations

147801

31
h-index

182427

51
g-index

56
all docs

56
docs citations

56
times ranked

16783
citing authors

#	ARTICLE	IF	CITATIONS
1	Clonal Hematopoiesis Is Associated With Higher Risk of Stroke. <i>Stroke</i> , 2022, 53, 788-797.	2.0	88
2	Association of clonal hematopoiesis with chronic obstructive pulmonary disease. <i>Blood</i> , 2022, 139, 357-368.	1.4	106
3	Clonal Hematopoiesis Analyses in Clinical, Epidemiologic, and Genetic Aging Studies to Unravel Underlying Mechanisms of Age-Related Dysfunction in Humans. <i>Frontiers in Aging</i> , 2022, 3, .	2.6	3
4	Mendelian randomization supports bidirectional causality between telomere length and clonal hematopoiesis of indeterminate potential. <i>Science Advances</i> , 2022, 8, eabl6579.	10.3	36
5	Human Coronary Plaque T Cells Are Clonal and Cross-React to Virus and Self. <i>Circulation Research</i> , 2022, 130, 1510-1530.	4.5	25
6	Longitudinal profiling of clonal hematopoiesis provides insight into clonal dynamics. <i>Immunity and Ageing</i> , 2022, 19, .	4.2	20
7	<i>TET2</i> -mutant clonal hematopoiesis and risk of gout. <i>Blood</i> , 2022, 140, 1094-1103.	1.4	57
8	Preventive Cardio-Oncology: Cardiovascular Disease Prevention in Cancer Patients and Survivors. <i>Current Treatment Options in Cardiovascular Medicine</i> , 2021, 23, 1.	0.9	5
9	Insights into clonal hematopoiesis and its relation to cancer risk. <i>Current Opinion in Genetics and Development</i> , 2021, 66, 63-69.	3.3	20
10	Clonal hematopoiesis associated with epigenetic aging and clinical outcomes. <i>Aging Cell</i> , 2021, 20, e13366.	6.7	72
11	<i>ZBTB33</i> Is Mutated in Clonal Hematopoiesis and Myelodysplastic Syndromes and Impacts RNA Splicing. <i>Blood Cancer Discovery</i> , 2021, 2, 500-517.	5.0	17
12	Infection makes micro-CHIPs into macro-CHIPs. <i>Cell Stem Cell</i> , 2021, 28, 1335-1336.	11.1	2
13	<i>Dnmt3a</i> -mutated clonal hematopoiesis promotes osteoporosis. <i>Journal of Experimental Medicine</i> , 2021, 218, .	8.5	81
14	Clonal Hematopoiesis is Associated with Reduced Risk of Alzheimer's Disease. <i>Blood</i> , 2021, 138, 5-5.	1.4	15
15	Clonal haematopoiesis: connecting ageing and inflammation in cardiovascular disease. <i>Nature Reviews Cardiology</i> , 2020, 17, 137-144.	13.7	215
16	Inherited causes of clonal haematopoiesis in 97,691 whole genomes. <i>Nature</i> , 2020, 586, 763-768.	27.8	376
17	Clonal hematopoiesis and non-hematologic disorders. <i>Blood</i> , 2020, 136, 1606-1614.	1.4	71
18	Clonal Hematopoiesis of Indeterminate Potential Reshapes Age-Related CVD. <i>Journal of the American College of Cardiology</i> , 2019, 74, 578-586.	2.8	57

#	ARTICLE	IF	CITATIONS
19	Clonal Hematopoiesis. <i>Journal of the American College of Cardiology</i> , 2019, 74, 567-577.	2.8	150
20	Clonal hematopoiesis in human aging and disease. <i>Science</i> , 2019, 366, .	12.6	590
21	Genetic regulation of gene expression and splicing during a 10-year period of human aging. <i>Genome Biology</i> , 2019, 20, 230.	8.8	57
22	Biological implications of clonal hematopoiesis. <i>Experimental Hematology</i> , 2019, 77, 1-5.	0.4	21
23	Itâ€™s in the blood. <i>Nature Medicine</i> , 2019, 25, 1184-1184.	30.7	0
24	Clonal hematopoiesis: Pre-cancer PLUS. <i>Advances in Cancer Research</i> , 2019, 141, 85-128.	5.0	35
25	Connections Between Clonal Hematopoiesis, Cardiovascular Disease, and Cancer. <i>JAMA Cardiology</i> , 2019, 4, 380.	6.1	42
26	CHIPping Away at the Pathogenesis of Heart Failure. <i>JAMA Cardiology</i> , 2019, 4, 5.	6.1	8
27	PPM1D-truncating mutations confer resistance to chemotherapy and sensitivity to PPM1D inhibition in hematopoietic cells. <i>Blood</i> , 2018, 132, 1095-1105.	1.4	160
28	Clonal Hematopoiesis. <i>Circulation Genomic and Precision Medicine</i> , 2018, 11, e001926.	3.6	43
29	Predicting progression to AML. <i>Nature Medicine</i> , 2018, 24, 904-906.	30.7	22
30	Loss-of-Function Mutations in Dnmt3a and Tet2 Lead to Accelerated Atherosclerosis and Convergent Macrophage Phenotypes in Mice. <i>Blood</i> , 2018, 132, 745-745.	1.4	21
31	Clonal Hematopoiesis Associated With Adverse Outcomes After Autologous Stem-Cell Transplantation for Lymphoma. <i>Journal of Clinical Oncology</i> , 2017, 35, 1598-1605.	1.6	339
32	Clonal Hematopoiesis and Risk of Atherosclerotic Cardiovascular Disease. <i>New England Journal of Medicine</i> , 2017, 377, 111-121.	27.0	1,738
33	Clonal Hematopoiesis and Atherosclerosis. <i>New England Journal of Medicine</i> , 2017, 377, 1400-1402.	27.0	33
34	Clonal hematopoiesis. <i>Seminars in Hematology</i> , 2017, 54, 43-50.	3.4	100
35	Clonal Hematopoiesis Associated with Adverse Outcomes Following Autologous Stem Cell Transplantation for Non-Hodgkin Lymphoma. <i>Blood</i> , 2016, 128, 986-986.	1.4	3
36	PPM1D Truncating Mutations Confer Chemotherapy Resistance in Hematopoietic Stem Cells, Which Is Reversible By PPM1D Inhibition. <i>Blood</i> , 2016, 128, 740-740.	1.4	0

#	ARTICLE	IF	CITATIONS
37	Clonal hematopoiesis of indeterminate potential and its distinction from myelodysplastic syndromes. <i>Blood</i> , 2015, 126, 9-16.	1.4	1,493
38	Clonal Hematopoiesis and Blood-Cancer Risk. <i>New England Journal of Medicine</i> , 2015, 372, 1071-1072.	27.0	57
39	Mutations in G protein $\hat{1}^2$ subunits promote transformation and kinase inhibitor resistance. <i>Nature Medicine</i> , 2015, 21, 71-75.	30.7	106
40	Age-Related Clonal Hematopoiesis Associated with Adverse Outcomes. <i>New England Journal of Medicine</i> , 2014, 371, 2488-2498.	27.0	3,474
41	MDS Is a Stem Cell Disorder After All. <i>Cancer Cell</i> , 2014, 25, 713-714.	16.8	16
42	Clonal Hematopoiesis with Somatic Mutations Is a Common, Age-Related Condition Associated with Adverse Outcomes. <i>Blood</i> , 2014, 124, 840-840.	1.4	1
43	Janus-like opposing roles of CD47 in autoimmune brain inflammation in humans and mice. <i>Journal of Experimental Medicine</i> , 2012, 209, 1325-1334.	8.5	147
44	The CD47-signal regulatory protein alpha (SIRPa) interaction is a therapeutic target for human solid tumors. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2012, 109, 6662-6667.	7.1	1,255
45	Macrophages as mediators of tumor immunosurveillance. <i>Trends in Immunology</i> , 2010, 31, 212-219.	6.8	215
46	Calreticulin Is the Dominant Pro-Phagocytic Signal on Multiple Human Cancers and Is Counterbalanced by CD47. <i>Science Translational Medicine</i> , 2010, 2, 63ra94.	12.4	591
47	Hematopoietic Stem and Progenitor Cells and the Inflammatory Response. <i>Annals of the New York Academy of Sciences</i> , 2009, 1174, 118-121.	3.8	18
48	CD47 Is an Adverse Prognostic Factor and Therapeutic Antibody Target on Human Acute Myeloid Leukemia Stem Cells. <i>Cell</i> , 2009, 138, 286-299.	28.9	1,371
49	CD47 Is Upregulated on Circulating Hematopoietic Stem Cells and Leukemia Cells to Avoid Phagocytosis. <i>Cell</i> , 2009, 138, 271-285.	28.9	1,282
50	Expression of <i>BCR/ABL</i> and <i>BCL-2</i> in myeloid progenitors leads to myeloid leukemias. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2003, 100, 10002-10007.	7.1	156
51	Modeling the temporal dynamics of clonal hematopoiesis. , 0, , .		0